BW Online | October 23, 2003 | AG Edwards Upgrades Lilly to 'Buy'

BW MAGAZINE Get Four Free Issues Register Subscribe Customer Service

ONLINE FEATURES Book Reviews BW Video Columnists Interactive Gallery Newsletters Past Covers Philanthropy Podcasts Special Reports BLOGS Auto Beat Bangalore Tigers Blogspotting Brand New Day Byte of the Apple Economics Unbound Eye on Asia Fine On Media Green Biz Hot Property Investing Insights Management IQ NEXT: Innovation NussbaumOnDesign Tech Beat Working Parents TECHNOLOGY J.D. Power Ratings Product Reviews Tech Stats Wildstrom: Tech Maven AUTOS Home Page Auto Reviews Classic Cars Car Care & Safety Hybrids INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip INVESTING Investing: Europe Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Hot Growth 100 Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS Undergrad Programs MBA Blogs MBA Profiles MBA Rankings Who's Hiring Grads

BW EXTRAS BW Digital BW Mobile BW Online Alerts Dashboard Widgets Podcasts RSS

RSS Feeds

Reprints/ Permissions Conferences Research Services

OCTOBER 23, 2003

STORY TOOLS

Search for business contacts:

PREMIUM SEARCH
Search by job title, geography and build a list of executive contacts

WORD ON THE STREET

AG Edwards Upgrades Lilly to 'Buy'
Analyst Albert Rauch says the drugmaker's new products and pipeline should provide strong earnings growth in 2004 and beyond

AG Edwards upgraded Eli Lilly to buy from hold.

Analyst Albert Rauch says the drugmaker's results are in line with estimates. He says Lilly has a portfolio of new drugs, and a pipeline of evolving products. These include Forteo (for severe osteoporosis), Cymbalta (for depression), Strattera (for attention deficit hyperactivity disorder), Cialis (for erectile dysfunction), intramuscular Zyprexa (for schizophrenia), and Symbyax (for bipolar depression).

He notes introduction of these products should provide Lilly with strong earnings growth in 2004 and beyond. Rauch sees $2.58 2003 earnings per share, $3.05 for 2004, and $3.57 in 2005.

All of the views expressed in this research report accurately reflect the research analyst's personal views regarding any and all of the subject securities or issuers. No part of analyst compensation was, is or will be, directly or indirectly related to the specific recommendations or views expressed in this research report.
Standard & Poor's Regulatory Disclosure

Any advice, analysis, or recommendations contained in articles labeled "Insight from Standard & Poor's" reflect the views of Standard & Poor's, which operates separately from and independently of BusinessWeek Online. It is possible that BWOL may from time to time publish information that is not consistent with advice, analysis, or recommendations that are published by Standard & Poor's. Standard & Poor's and BusinessWeek Online are each units of The McGraw-Hill Companies, Inc.

BW MALL SPONSORED LINKS

Mutual Funds at Fidelity Benefit from years of mutual fund management experience.
100% Accurate Penny Stocks Free penny stock picks exploding up to 803%...Totally Free...Must see to believe
Earn From 2.02% to 2.32% With GE Capital Corporation. Not An Offer Of Securities For Sale.
RJO Futures’ Options Strategy Guide This Free Guide Includes Strategies for Using Options on Futures and Much More.
FREE Life Insurance Quotes from MetLife Request a Free Quote from MetLife. $250,000 of Coverage as Low as $12 per Month

Buy a link now!

Get BusinessWeek directly on your desktop with our RSS feeds. XML

Add BusinessWeek news to your Web site with our headline feed.

Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video.

To subscribe online to BusinessWeek magazine, please click here.

Learn more, go to the BusinessWeekOnline home page